Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Analysis of SEER data from 2000-2021 reveals incidence, survival trends, and demographic disparities in US patients with myeloproliferative neoplasms, highlighting improved outcomes particularly in primary myelofibrosis and areas for furthe
Vulvar cancer exhibits significant recurrence rates, predominantly local, with survival declining sharply after recurrence. Awareness of recurrence-associated symptoms enhances early detection. Surgery remains pivotal in management, with fr
Charcot neuro-osteoarthropathy (CNO) in people with diabetes is linked to frequent emergency hospitalizations, substantial risk of limb amputation, and reduced survival, highlighting urgent need for intensified multidisciplinary care.
The ANDROMEDA phase 3 trial demonstrates that adding subcutaneous daratumumab to VCd therapy markedly improves hematologic and organ responses, leading to better progression-free and overall survival in newly diagnosed AL amyloidosis patien
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
Enfortumab vedotin (EV) therapy in advanced urothelial carcinoma is frequently associated with cutaneous adverse events (cAEs). These EV-induced skin toxicities correlate independently with improved progression-free and overall survival, ev
A large Texas registry study found that treatment delays beyond 6 weeks were independently associated with worse survival in early-onset colorectal cancer, with language barriers identified as a potentially modifiable contributor.
This study found that advanced high-grade serous ovarian cancers from short-term survivors had more fibroblasts and stromal invasion signals, while tumors from long-term survivors showed stronger immune pathways, suggesting the tumor microe
A nationwide French cohort study reveals that advanced NSCLC patients completing 2 years of pembrolizumab maintain excellent survival outcomes, with most remaining treatment-free and immunotherapy rechallenge being uncommon.
In 2026, approximately 2.1 million new cancer cases and 626,140 deaths are projected in the U.S. Advances in prevention, early detection, and treatment have increased survival rates and averted millions of deaths, yet disparities and rising
Randomised trials show breast surgery improves local disease control but not overall survival in de novo metastatic breast cancer.
A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated
A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets
A large linkage of Chinese national registries (628.4 million population) estimates 43,275 acute leukaemia cases in 2019, describes age-specific incidence peaks in early childhood and older age, reports major survival gains for children and
AEDs improve survival in in-home cardiac arrests with shockable rhythms but are not cost-effective for widespread private home use at current prices and incidence rates, per a large US cohort study using CARES data.
This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.
The APOE ε4 allele significantly reduces survival in Parkinson’s disease patients independently of dementia, linked to mitochondrial dysfunction and ER stress in PD models.
A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.
This analysis compares survival in young women with early-stage endometrial cancer treated with fertility-preserving hormonal therapy versus hysterectomy, highlighting survival equivalence in women under 40 years and increased mortality ris
A phase II trial reveals that high-dose twice-daily thoracic radiotherapy (60 Gy/40 fractions) significantly improves survival without increasing severe toxicity compared to the standard dose (45 Gy/30 fractions) in limited-stage SCLC patie